The Traderszone Network

Published in TZ Latest News 24 April, 2017 by The TZ Newswire Staff

Earnings Outlook: Pricey rare disease drug’s launch will be likely focus of Biogen earnings

Spinraza’s price tag — up to $750,000 in the first year — has attracted criticism.
read more